-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
[Pharmaceutical Network Industry News] According to statistics, the number of newly approved domestic drug approvals from January to July 2022 is 584 (referring to the approval for listing, and the rest of the new approvals are not included in the statistical scope for the time bein.
Among them, there are 33 new drug approvals, and chemical drugs and biological drugs are still the main force; 551 generic drugs, and the total proportion of categories 3 and 4 is as high as 9
On the whole, there are 115 new products approved for nervous system dru.
Among them, CSPC performed very we.
Recently, Gabapentin Capsules and Lacosamide Injection, which were produced as imitations of Category 4, have been approved for marketing, and are deemed to have passed the consistency evaluati.
It is understood that both gabapentin capsules and lacosamide injection are anti-epileptic drugs, and CSPC's lacosamide injection is the second domestically produced dr.
It is worth mentioning that, since 2022, CSPC has approved 10 newly registered and classified generic drugs, including gabapentin capsules, lacosamide injection, vortioxetine hydrobromide tablets, Pramipexole Hydrochloride Sustained-Release Tablets, Tenofovir Fumarate Propofol Tablets, Doxofylline Injection, Donepezil Hydrochloride Tablets, Esomeprazole Sodium for Injection, Nifedipine Controlled-Release Tablets, Methanesulfonic Acid Lenvatinib capsul.
Among them, 5 varieties belong to nervous system dru.
In addition to nervous system drugs, nearly 100 systemic anti-infective drugs were declared and approved for marketing from January to Ju.
At present, Kelun Pharmaceutical has achieved remarkable results in the approval of anti-infective dru.
It is understood that 32 new drugs (21 category 1 new drugs) are in the clinical application stage and above, 4 have entered the phase III clinical stage and above, and two ADC drugs have achieved overseas authorization; 82 over-evaluated varieties (34 The first one) to focus on two billion-dollar marke.
These 82 varieties cover 11 major categories of treatment, of which 27 varieties focus on systemic anti-infective dru.
The data shows that in 2021, the market size of chemical drugs and nervous system drugs in the three major terminals and six major markets (including Chinese public medical institution terminals, Chinese urban physical pharmacy terminals, and Chinese online pharmacy terminals) will exceed 100 billion yuan, with a growth rate of about
; The market size of systemic anti-infective drugs is more than 170 billion yuan, with a growth rate of 6
The industry believes that as more new products are approved, the two billion-dollar markets and related companies will usher in more opportunities and new challeng.
It is worth noting that obtaining new approvals for pharmaceutical companies can improve market competitivene.
Therefore, many companies are currently accelerating the acquisition of new approvals through various for.
It is reported that on August 2, TusPharm announced that the company intends to acquire 100% equity of Guangdong Xantong for a consideration of 220 million yuan in cash, and Guangdong Xantong holds a total of 16 Chinese medicine approval documen.
Affected by this news, on August 3, the opening of TusHoldings Pharmaceutical .
, L.
rose sharply and quickly reached the daily lim.
It is expected in the industry that 2022 will be a year of active approval transactions under the background that the reform of the domestic pharmaceutical industry continues to accelerate, with transfers and acquisitions between approvals or a new clim.
But for enterprises, there will also be more new challenges, such as how to resume production and how to find a variety of approval numbers that meet their nee.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyo.
Among them, there are 33 new drug approvals, and chemical drugs and biological drugs are still the main force; 551 generic drugs, and the total proportion of categories 3 and 4 is as high as 9
On the whole, there are 115 new products approved for nervous system dru.
Among them, CSPC performed very we.
Recently, Gabapentin Capsules and Lacosamide Injection, which were produced as imitations of Category 4, have been approved for marketing, and are deemed to have passed the consistency evaluati.
It is understood that both gabapentin capsules and lacosamide injection are anti-epileptic drugs, and CSPC's lacosamide injection is the second domestically produced dr.
It is worth mentioning that, since 2022, CSPC has approved 10 newly registered and classified generic drugs, including gabapentin capsules, lacosamide injection, vortioxetine hydrobromide tablets, Pramipexole Hydrochloride Sustained-Release Tablets, Tenofovir Fumarate Propofol Tablets, Doxofylline Injection, Donepezil Hydrochloride Tablets, Esomeprazole Sodium for Injection, Nifedipine Controlled-Release Tablets, Methanesulfonic Acid Lenvatinib capsul.
Among them, 5 varieties belong to nervous system dru.
In addition to nervous system drugs, nearly 100 systemic anti-infective drugs were declared and approved for marketing from January to Ju.
At present, Kelun Pharmaceutical has achieved remarkable results in the approval of anti-infective dru.
It is understood that 32 new drugs (21 category 1 new drugs) are in the clinical application stage and above, 4 have entered the phase III clinical stage and above, and two ADC drugs have achieved overseas authorization; 82 over-evaluated varieties (34 The first one) to focus on two billion-dollar marke.
These 82 varieties cover 11 major categories of treatment, of which 27 varieties focus on systemic anti-infective dru.
The data shows that in 2021, the market size of chemical drugs and nervous system drugs in the three major terminals and six major markets (including Chinese public medical institution terminals, Chinese urban physical pharmacy terminals, and Chinese online pharmacy terminals) will exceed 100 billion yuan, with a growth rate of about
; The market size of systemic anti-infective drugs is more than 170 billion yuan, with a growth rate of 6
The industry believes that as more new products are approved, the two billion-dollar markets and related companies will usher in more opportunities and new challeng.
It is worth noting that obtaining new approvals for pharmaceutical companies can improve market competitivene.
Therefore, many companies are currently accelerating the acquisition of new approvals through various for.
It is reported that on August 2, TusPharm announced that the company intends to acquire 100% equity of Guangdong Xantong for a consideration of 220 million yuan in cash, and Guangdong Xantong holds a total of 16 Chinese medicine approval documen.
Affected by this news, on August 3, the opening of TusHoldings Pharmaceutical .
, L.
rose sharply and quickly reached the daily lim.
It is expected in the industry that 2022 will be a year of active approval transactions under the background that the reform of the domestic pharmaceutical industry continues to accelerate, with transfers and acquisitions between approvals or a new clim.
But for enterprises, there will also be more new challenges, such as how to resume production and how to find a variety of approval numbers that meet their nee.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyo.
